PITTSBURGH, July 20 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL) today announced that the U.S. Food and Drug Administration has granted final approval for Mylan Pharmaceuticals Inc.'s Abbreviated New Drug Application for Meloxicam Tablets, 7.5 mg and 15 mg.

Meloxicam Tablets are indicated for the relief of the signs and symptoms of osteoarthritis. They are the AB-rated generic equivalent of Boehringer Ingelheim's Mobic^® Tablets, which had annual U.S. sales of approximately $1.1 billion for the 12 months ending March 31, 2006.

This product will be shipped immediately.

Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries: Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc. Mylan develops, licenses, manufactures, markets and distributes an extensive line of generic and proprietary products.

For more information about Mylan, please visit www.mylan.com.

SOURCE Mylan Laboratories Inc.
07/20/2006
CONTACT: Patrick Fitzgerald, or Kris King, of Mylan Laboratories Inc.
+1-724-514-1800
Web site: http://www.mylan.com
(MYL)